Who is sponsoring NCT00643656?

NCT00643656 is sponsored by Air Liquide Santé International.

What condition does NCT00643656 study?

NCT00643656 studies Liver Biopsy.

What drugs are being tested in NCT00643656?

Interventions: Kalinox 170 bar, Mix of 50% oxygen and 50% nitrogen.

What is the status of NCT00643656?

NCT00643656 is currently COMPLETED.

Last reviewed 2025-03-11 · How we verify

Study of the Efficiency of Kalinox 170 Bar During Liver Biospy of Focal Lesion

NCT00643656 Phase 4 COMPLETED

A 50% nitrous oxide / 50% oxygen premix is administrated to the patient during the realization of liver biopsy in order to relax him and to reduce his pain during this painful medical treatment. This single investigator centre and national clinical trial is done blindly : half of patients will receive 50% nitrous oxide / 50% oxygen premix and half of them a placebo gas (mixture of 50% oxygen and 50% nitrogen). 94 patients will be included in this clinical protocol.

Details

Lead sponsor	Air Liquide Santé International
Phase	Phase 4
Status	COMPLETED
Enrolment	94
Start date	2007-10
Completion	2008-12

Conditions

Liver Biopsy

Interventions

Kalinox 170 bar
Mix of 50% oxygen and 50% nitrogen

Primary outcomes

Pain measurement by using Visual Analog Scale (VAS) — At the end of the liver biospy

Countries

France